There is no adequate competition, this is an orphan drug that will sustain at most one producer. Fun fact: most generics are sourced to very few producers becau

There is no adequate competition, this is an orphan drug that will sustain at most one producer. Fun fact: most generics are sourced to very few producers because margins are so low, competition is working. There are similarities to fine chemical shortages: http://blogs.sciencemag.org/pipeline/archives/2010/06/16/sparteine_and_other_fine_chemical_shortages http://blogs.sciencemag.org/pipeline/archives/2010/06/16/spa... The world can do without sparteine, but orphan drugs call for regulation as natural monopolies, or even government subsidies.